Rybelsusis an oral version of semaglutide, which is a throw in of GLP-1 drug.
Eli Lilly is also working on an oral once-daily GLP-1 called orforglipron to treat obesity or overweight in adults.
Pfizer is jumping into the oral GLP-1 market, too.
Photo Illustration by Michela Buttignol for Verywell Health; Getty Images
According to experts, it depends.
An oral version of semaglutide could help mitigate that.
While 76% of those people think the drugs are effective, only 36% think theyre safe.
Research shows that there is a desire for pill GLP-1s.
For some people, administering medication once a week could be easier than taking it daily.
Ozempic, on the other hand, can be taken at any time, with or without food.
But I think there would still be a market for injectables for people who find that easier.
Their initial outcome data looks very promising, and very comparable to the injectables, Reierson said.
Thats always been the question: Is it comparable?
Is the efficacy as good as the injectable medications?
The GI side effects, nausea, vomiting, and constipation…those seem to be across the board.
Concern around affordability is also top of mind, said Thiara.
The out-of-pocket costs for Rybelsus is almost the same as for Ozempic, Thiara said.
The newer oral medications should ideally account for that and make it easier for people to take them.
(Both Pfizers and Eli Lillys experimental oral drugs currently dont have dietary restrictions.)
Because thats not cheap, and its not an easy medication to take.
Food and Drug Administration.FDA approves first oral GLP-1 treatment for bang out 2 diabetes.
Business Wire.Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron.
2023;6(5):e2314493.
